 |
Early Identification and Treatment of Mineral and Bone Disorders in CKD Stages 3 and 4 CME/CE Author Information and Disclosures Release Date: January 31, 2008; Valid for credit through January 31, 2009 | Physicians - maximum of 2.0 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 2.0 nursing contact hours (1.0 contact hours are in the area of pharmacology);
Pharmacists - 2.0 ACPE continuing education credits for pharmacists (0.2 CEUs)
Dietitians - 1.0 CPEUs | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME/CE Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Describe the pros and cons of current measures of renal dysfunction
- Explain the independent risk factors for mortality in early chronic kidney disease (CKD), which include secondary hyperparathyroidism and phosphorus
dysregulation
- Describe the pathophysiology of CKD-MBD and the importance of monitoring biochemical parameters (parathyroid hormone [PTH], calcium, phosphorus)
- Evaluate the difference between 25D repletion and 125D prescription in early CKD patients
- Discuss current data on effective treatment strategies to maintain consistent control of PTH, calcium, and phosphorus levels in early CKD patients
Authors and Disclosures Anjay Rastogi, MD, PhD
Disclosure: Anjay Rastogi, MD, PhD, has disclosed that he has served as a consultant and on the speaker’s bureau for Genzyme, Ortho Biotech, GlaxoSmithKline, and AstraZeneca. Anne G. Le, PharmD, RPh
Disclosure: Anne G. Le, PharmD, RPh, has disclosed no
relevant financial relationships. Allen R. Nissenson, MD
Disclosure: Allen R. Nissenson, MD, has disclosed that he owns stock, stock options, or bonds in Advanced Magnetics. Dr. Nissenson has also disclosed that he has received grants for educational activities from Amgen, Roche, and OBI. Dr. Nissenson has also disclosed that he has served as an advisor or consultant to Amgen, Affymax, Fibrogen, OBI, Roche, Promotic,
Advanced Magnetics, and Davita. Richard A. Sherman, MD
Disclosure: Richard A. Sherman, MD, has disclosed that he has received grants for educational activities from and has served as an advisor or consultant to Shire Pharmaceuticals. Susan Smith, RN, PhD
Disclosure: Susan Smith, RN, PhD, has disclosed no relevant financial relationships.
Laura L. Engles-Horton, PharmD
Disclosure: Laura L. Engles-Horton, PharmD, has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
This Activity is sponsored by Medscape Continuing Education Provider Unit. Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded 2.0 contact hour(s) of continuing nursing education for RNs and APNs; 1.0 contact hours are in the area of pharmacology. Provider Number: 6FDKKC-PRV-05
Contact This Provider
|
|
 Medscape is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Medscape designates this continuing education activity for 2.0 contact hour(s) (0.2 CEUs) (Universal Program Number 461-000-08-006-H01-P).). This program has been approved by the Commission on Dietetic Registration for 1.0 CPEUs.
Contact This Provider
|
|
